About Admin

David experienced an adverse event to the the fluoroquinolone Levaquin in 2007 at age 46. Prior to, he was a healthy law enforcement official. Now, disabled with drug induced mitochondrial disease/dysfunction, he is an FQ patient safety advocate, citizen scientist, FQ researcher, author, and commentator. He has contributed to case studies and published academic papers on the FQ’s in the BMJ, European Journal of Medicine, The Journal of Community and Supportive Oncology, Oxford Academic Clinical infectious Diseases, and contributed data to many more outlets.

Fluoroquinolones, FDA Memo Highlights Damning Evidence

Recently an internal memo dated April 17, 2013, issued by the Food and Drug Administration’s Center Drug Evaluation and Research, Office of Surveillance and Epidemiology, was obtained through the freedom of information act shows the FQs in a damning light.

Hopeless or hopeful, Fluoroquinolones and DNA Adduction, Part Deux

Since our physiology is not static and things such as enzyme levels and trace mineral are in a constant state of flux, not to mention genetic variances, all which affect metabolization, combined with the fact that the FQ molecule is very complex, there is no way of determining if the same decomposed and identifiable compound will form an adduct in each person.

Nurse Practitioners, Not For Me

I would have to say that we are one of the most complex subset of patients that can be seen by a physician. More often than not, we often leave the average physician scratching his head as to how to diagnose or treat our condition. Keeping that context in mind, I have determined that I will never see another nurse practitioner again.